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Bromodomain-containing protein 4 (Brd4) and hexamethylene bisacetamide (HMBA) inducible protein 1 (HEXIM1) are two
opposing regulators of the positive transcription elongation factor b (P-TEFb), which is themastermodulator of RNApolymerase II
during transcriptional elongation.While Brd4 recruits P-TEFb to promoter-proximal chromatins to activate transcription,HEXIM1
sequesters P-TEFb into an inactive complex containing the 7SK small nuclear RNA. Besides regulating P-TEFb’s transcriptional
activity, recent evidence demonstrates that both Brd4 andHEXIM1 also play novel roles in cell cycle progression and tumorigenesis.
Here we will discuss the current knowledge on Brd4 andHEXIM1 and their implication as novel therapeutic options against cancer.
1. Introduction
Transcriptional regulation is a fundamental process for con-
verting the genetic codes into RNA synthesis for proper
cellular functions in an organism.The main cellular machin-
ery for transcribing all protein-coding genes is the RNA
polymerase II (RNAPII). Due to the enormous numbers of
different genes to be coordinately expressed at any given
time, the transcriptional activity of RNAPII is subjected to
meticulous modulation by a myriad of regulators. One of the
most significant RNAPII regulators identified to date is the
positive transcriptional elongation factor b (P-TEFb). P-TEFb
controls the transition of RNAPII from promoter proximal
pausing to productive elongation for efficient full-length
mRNA synthesis [1, 2]. At the early phase of mRNA synthesis
shortly after the initiation of transcription, the progression
of RNAPII is paused near the transcriptional start site by the
concerted actions of the negative elongation factor (NELF)
[3], DRB (5,6-dichloro-1-b-D-ribofuranosyl-benzimidazole)
sensitivity-inducing factor (DSIF) [4], and Gdown1 [5]. In
order to release the paused RNAPII, P-TEFb is recruited
to the promoter, where its kinase activity phosphorylates
the C-terminal domain (CTD) of RNAPII and the negative
elongation factors NELF and DSIF [6, 7]. These phosphory-
lation events are believed to induce conformational changes
that allow RNAPII to escape promoter proximal pausing
and enter the productive phase of transcriptional elonga-
tion. More importantly, the pausing of RNAPII serves as
a rate-limiting step for transcriptional regulation, especially
for inducible genes, such as those induced by stress and
inflammatory responses [8, 9]. Cells treated with flavopiridol,
the most potent and selective P-TEFb inhibiting compound,
result in inhibition of 60–70% of RNAPII transcription [10,
11]. Furthermore, genome-wide studies find that RNAPII
occupies the promoters of most protein-coding genes in
Drosophila andhuman embryonic stem cells without entering
into productive elongation [12–16].Therefore, P-TEFb plays a
critical role in RNAPII regulation and has a broad impact on
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Figure 1: Regulation of P-TEFb activity by its positive regulator HEXIM1 and negative regulator Brd4.
Besides controlling the expression of cellular genes, P-
TEFb is also required for transcriptional regulation of a
number of viruses. The best-known example is the human
immunodeficiency virus (HIV). Mathews and coworkers
detected two classes of HIVpromoted cytoplasmic RNAs,
a fulllength transcript, and a short transcript ending 55–
59 nucleotides from the start site of transcription [17].
This observation clearly implies that transcription of HIV
may also be regulated at the elongation stage. Later studies
demonstrate that the HIV Tat protein recruits P-TEFb to the
viral promoter and triggers the transition of RNAPII into
productive elongation, resulting in the generation of full-
length viral transcripts [18–20].
P-TEFb is composed of cyclin-dependent kinase 9
(CDK9) and its regulatory cyclin partner cyclin T1 [21,
22]. The Ser2 of the RNA Polymerase II CTD repeat (i.e.,
YSPTSPS) has been identified as the P-TEFb phosphorylation
site during elongation [23, 24]. CDK12 is also a CTD Ser2
kinase; however, it is not within the scope of this review
[25]. CDK9 exists as two isoforms, a major 42 kDa form
and a minor 55 kDa form [26]. Besides cyclin T1, minor
CDK9-associated cyclins, such as T2a, T2b, and K, are also
present but at much lower levels in many cell types [27, 28].
Given the important roles of P-TEFb in RNAPII-dependent
transcription, P-TEFb’s activity is constantly beingmodulated
through dynamic association with positive and negative reg-
ulators. Among these factors, hexamethylene bisacetamide
(HMBA) inducible protein 1 (HEXIM1) and bromodomain-
containing protein 4 (Brd4) are the two major regulators
of P-TEFb. In log-phase HeLa cells, roughly half of the P-
TEFb is sequestered into an inactive complex containing
the kinase inhibitor HEXIM1 [29, 30] and other auxiliary
proteins, MePCE [31], and LARP7 [32] held together by
the non-coding 7SK small nuclear RNA (snRNA) (Figure 1).
HEXIM1 exerts its inhibitory function on P-TEFb only when
associated with the 7SK snRNA, while neither 7SK nor
HEXIM1 alone instigates any effects [29, 33]. It has been
proposed that association of the 7SK snRNA with HEXIM1
leads to a conformational change that renders the cyclin T1-
binding domain of HEXIM1 accessible for P-TEFb binding
[34]. Besides the inactive pool of P-TEFb, the remaining
half of P-TEFb is transcriptionally active and bound to
Brd4. Brd4 functions to recruit P-TEFb to active promoter
through its affinity to acetylated histones [35, 36] (Figure 1).
The distribution of P-TEFb between the active and inactive
complexes is a dynamic process that can be rapidly changed
in response to cellular stress and transcriptional demand.
The regulation of P-TEFb by Brd4 and HEXIM1 has been
extensively reviewed elsewhere [37, 38]. In this review, wewill
focus on the recent findings on Brd4/HEXIM1 with respect
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to their newly discovered roles in cell cycle progression and
cancer.
2. Brd4
During eukaryotic transcription, the epigenetic information
packaged in chromatin is interpreted by “reader” proteins.
These proteins contain specialized domains for recognizing
the vocabularies of histone codes that are composed of com-
binatorial histone modifications [39]. Histone acetylation,
for instance, is specifically recognized by protein module
termed bromodomain [40]. In human, there are a total
of 61 different bromodomains. These bromodomains are
evolutionarily conserved and present in 46 distinct proteins,
which belong to eight families: histone acetyltransferases,
ATP-dependent chromatin-remodeling complexes, helicases,
methyltransferases, transcriptional coactivators, transcrip-
tional mediators, nuclear-scaffolding proteins, and the BET
family proteins [41, 42].
Brd4 is a ubiquitously expressed nuclear protein that
belongs to the BET protein family. Brd4 contains two N-
terminal tandem bromodomains (BDI and BDII) and an
extraterminal domain (ET) [43]. The ET domain functions
as a motif that interacts with WHSC1L1 (Wolf-Hirschhorn
syndrome candidate 1-like 1 or NSD3) for the regulation
of H3K36 methylation [44]. Early reports indicated that
the bromodomains of Brd4 are essential for its binding
to chromatin via acetylated histones [45, 46]. A recent
study with systematic peptide array screening combined with
crystallography further revealed that the first bromodomain
BD1 of Brd4 contributes mostly for its association with acety-
lated chromatin by simultaneous binding and recognition of
diverse diacetyl-containing histones [41].
2.1. The Dual Faces of Brd4: Cell Cycle Control and Transcrip-
tional Regulation. Consistent with its chromatin targeting
nature, Brd4 was originally identified as a mitotic chromo-
some associated protein (MCAP) as it was found persistently
associated with acetylated chromosomes during mitosis in
a number of cell lines [45, 46]. Later studies demonstrated
that this association is critical for the rapid expression of
early G1 genes upon exiting mitosis [47–50]. Although the
mechanism is still unclear, Brd4 has been proposed to play
an important role in transmitting the epigenetic memory
across cell division by bookmarking the transcriptionally
active genes [49, 51, 52]. Besides the bookmarking function,
the association of Brd4 with mitotic chromosome is also
important for Brd4’s function in maintaining chromatin
compaction [50, 53] and in facilitating the even segregation
of viral DNAs into daughter cells during cell division [54].
Distinct from the other BET proteins, Brd4 contains a
unique PID domain at its extreme C-terminus for interacting
with P-TEFb [55]. Increasing evidence indicates that for
the expression of many signal-inducible genes, the rate-
limiting step is not transcription initiation but elongation
[56]. After initiation is accomplished, RNAPII is poised at the
promoter-proximal regions, and signal-induced activation
and recruitment of P-TEFb to these regions convert the
stalled RNAPII into productive elongation mode [57, 58].
In cell, P-TEFb is tightly regulated by being sequestrated
in the nucleoplasma as an inactive ribonucleoprotein com-
plex that contains the 7SK snRNA, HEXIM1, LARP7, and
MePCE [59, 60] (Figure 1). Upon stimulation, P-TEFb is
liberated from the inactive 7SK complex by the dephospho-
rylation of CDK9 T-loop through the concerted actions of
PP2B and PP1𝛼 (protein phosphatase 2B and 1𝛼) pathways
or by the phosphorylation of HEXIM1 through PI3D/Akt
or PKC kinase signaling pathways [61–63]. Subsequently,
the liberated P-TEFb is recruited by Brd4 onto promoter-
proximal region to modulate the processivity of RNAPII
[29, 35, 36, 61, 64]. In line with its role in recruiting P-
TEFb for stimulation of transcriptional elongation, Brd4 has
been shown to be indispensable for cell proliferation [47–49],
as well as the integration and transcription of HIV-1 [65–
70], inflammatory response [8, 71, 72], cardiac hypertrophy
[73, 74], and DNA damage repair [75, 76].
2.2. Brd4, a Novel Drug Target for Cancer Therapy. Accu-
mulating studies have revealed the critical roles of Brd4 in
cancer development [77, 78]. The first clue linking Brd4
with cancer was the finding of Brd4-NUT fusion onco-
gene which was recognized as an important mechanism
in NUT midline carcinoma (NMC), an aggressive form of
squamous carcinoma [79, 80]. NMC is genetically defined
by the chromosomal rearrangements of the gene NUT (C15
or f55). In about 75% of NMCs, most of the NUT gene’s
coding region on chromosome 15q14 is fused with Brd4
[81–83]. Besides the chromosomal rearrangement-induced
NUT midline carcinomas, other studies have also indicated
that Brd4 may contribute to cancer development through
different mechanisms. For example, deleting the proline-rich
region of Brd4 could promote epithelial-to-mesenchymal
transition and stem cell-like conversion [84, 85]. The inter-
action of the first bromodomain (BD1) of Brd4 with acety-
lated NF-𝜅B/RelA leads to constitutively active NF-𝜅B that
enhances cancer cell proliferation [86]. Moreover, a study
using shRNA library targeting 243 known chromatin regula-
tors identified Brd4 as a required factor for the maintenance
of acute myeloid leukemia (AML). Knockdown of Brd4
exhibited a robust antileukemic activity against AML in vitro
and in vivo [87, 88]. Other recent studies with small molecule
inhibitors of the BET proteins, such as JQ1 and I-BET 151,
revealed the critical role of Brd4 in the development of
several hematopoietic and somatic cancers, such as Burkitt’s
lymphoma,multiplemyeloma [88–91], melanoma [92], colon
[93], and breast cancer [84]. The mode of action of the BET
inhibitors may be, at least in part, due to the inhibition
of transcription of the oncogene, C-MYC [89–91]. A recent
study shows that treatment with JQ1 results in preferential
loss of Brd4 at super-enhancers and consequent transcription
elongation defects that preferentially impacted genes with
super-enhancers, including MYC [94]. Accordingly, small
molecule inhibitors targeting Brd4 have been proven to be a
promising drug for cancer therapy [77, 95].
2.3. The Role Switching of Brd4: From Chromatin Targeting
to Transcriptional Regulation. The diverse biological roles











H3S10ph-associated factor X that blocks HDACs














to release X factor
K8
K5
Activated HDACs deacetylates H4K5ac/K8ac to
release Brd4 for enhancing transcription
XPP1𝛼
(b)
Figure 2: Regulation of the association between Brd4 and chromatins in the nonstimulated (a) and stimulated (b) cells.
of Brd4 have been proposed to rely on its functional
transition between chromatin targeting and transcriptional
regulation [43, 51]. Consistent with this notion, our recent
study showed that, besides P-TEFb, the availability of Brd4
is also highly regulated [64]. Surveys of a variety of cell
lines show that almost all Brd4 is bound to chromatin in
interphase and there is limited chromatin-free Brd4 available
in the unstimulated state. Upon stress induction (such as
UV or HMBA treatment), Brd4 is released from chromatin
and subsequently interacts and recruits signal-activated P-
TEFb to enhance transcriptional elongation of inducible
genes [64]. Intriguingly, stress treatment also triggers global
deacetylation of acetylated-lysine 5 and 8 of nucleosomal
histone H4 (H4K5ac/K8ac) [64]. In our recent study, these
two acetylated sites are identified as the Brd4 binding sites
(unpublished data), suggesting that the signal-controlled
dynamic modification of nucleosomal histone is important
for Brd4’s role transition from chromatin targeting to tran-
scriptional regulation.
Since the release of chromatin-bound Brd4 correlates
with the signal-induced deacetylation of Brd4 binding sites
H4k5ac/K8ac, the epigenetic regulation of Brd4’s role switch-
ing apparently could simply be the deacetylation of Brd4’s
binding sites by histone deacetylases (HDACs). Through
in vivo experiments and in vitro biochemical assays, we
unexpectedly find that both PP1𝛼 and HDACs (HDAC1, 2,
and 3 of class I HDAC) signaling pathways are essential for
releasing chromatin-bound Brd4. Moreover, this releasing
process relies on trans-histone crosstalk between H3S10ph
(phosphorylated-serine 10 of histone H3) and H4K5ac/K8ac,
which connects PP1𝛼 and HDACs to control the functional
transition of Brd4 (Figure 2). In the nonstressed state, a
H3S10ph-associated factor (referred as “X factor”) prevents
HDAC1/2/3 from accessing H4K5ac/K8ac for deacetylation
and hence locks up the majority of Brd4 onto chromatin
(Figure 2(a)). During stress response, the PP1𝛼 pathway
dephosphorylates H3S10ph, and the “X factor” departs from
the nucleosome. This allows stress-activated HDAC1/2/3
to access and deacetylate H4K5ac/K8ac, thereby releas-
ing chromatin-bound Brd4 for subsequent stimulation of
inducible gene expression (Figure 2(b)). In this context, the
dephosphorylation of H3S10ph governs Brd4’s role switch-
ing from chromatin targeting to regulating inducible gene
expression.
For more than two decades, the signal-induced phospho-
rylation of H3S10 has been regarded as a positive epigenetic
mark for transcriptional activation of inducible genes [96–
100]. In contrast, we found that the dephosphorylation of
H3S10ph is the key to Brd4-mediated expression of inducible
genes ([64] and unpublished data). Although apparently
contradictory, these events are likely to occur at different
regions of the genome. We discover that, despite a significant
decrease in global H3S10ph during stress treatments, there is
an increased chromatin binding of 14-3-3 (unpublished data),
an H3S10ph-associated protein that functions as a scaffold
for recruiting chromatin remodeling factors [78, 100]. This
result indicates that 14-3-3 and Brd4 are associated with
different nucleosomes, and hence 14-3-3 is unlikely to be
the “X factor”. Moreover, signal-induced H3S10 phospho-
rylation usually correlates with the chromatin remodeling
of promoter [97], which occurs prior to transcription ini-
tiation. However, we observed that stress-induced H3S10ph
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dephosphorylation enables Brd4 to augment transcription
elongation [64], an event subsequent to initiation.Hence, one
may envision that for a small fraction of nucleosomes located
at the promoter or enhancer regions of inducible genes, the
signal-induced H3S10 phosphorylation facilitates chromatin
remodeling for subsequent transcription initiation, whereas
the global decline in H3S10ph may have distinct function in
governing Brd4’s release for subsequent P-TEFb recruitment
and transcription elongation. As Brd4 represents a novel and
promising drug target for cancer therapy, it is crucial to
thoroughly elucidate its role in cell cycle progression and in
epigenetic and transcriptional regulation.
3. HEXIM1
HEXIM1was first identified in 1999 and the potential involve-
ment of HEXIM1 in differentiation and cardiac development
was suggested [101, 102]. However, the major biological func-
tion of HEXIM1 as the inhibitor of P-TEFb was revealed four
years later by two research groups led by Olivier Bensaude
and Qiang Zhou [29, 30]. Recent evidence demonstrated
a role of HEXIM1 in cancers and regulation of the p53
pathway through the P-TEFb-dependent and -independent
mechanisms [38, 103].
3.1. HEXIM1 as a Potential Tumor Suppressor. The potential
involvement of HEXIM1 in cancers was first reported by
Montano and coworkers in 2003. They identified HEXIM1
as a novel binding protein of estrogen receptor 𝛼 (ER𝛼) in
a yeast two-hybrid screen using a cDNA library of MCF7
breast cancer cells. Since estrogens downregulated HEXIM1
expression at both protein and mRNA levels, HEXIM1 was
also named estrogen downregulated gene 1 (EDG1) [104].
Estrogens are known to play a critical role in the growth
of breast cancers and exert their effects by binding to their
specific nuclear receptors. The ligand-bound ERs function
as a transcriptional activator and upregulate several genes
required for cell proliferation, such as cyclin D1 and C-MYC
[105, 106].
ER𝛼 has been widely targeted in breast cancer therapy
since it is present inmore than half of breast tumors [107, 108].
Therefore, a potential role of HEXIM1 in regulating ER𝛼 in
breast cancers was suggested. Breast cancer cells exhibited
lower HEXIM1 expression when compared to normal breast
epithelial tissue, and overexpression of HEXIM1 inhibited
growth of both normal and breast cancer cells [104]. The
molecular mechanism of cell growth inhibition by HEXIM1
was later elucidated.HEXIM1 interactedwith ER𝛼 through its
C-terminal region and inhibited the activity of ligand-bound
ER𝛼 [109]. In addition, interaction between cyclin T1 and
ER𝛼 was identified, suggesting the requirement of P-TEFb
in regulating ER𝛼 activity during transcriptional activation
[109]. Based on these findings, it was proposed that ER𝛼
might compete with HEXIM1 for binding to cyclin T1. Thus,
the transcriptional activity of ER𝛼 depends on its association
with P-TEFb (i.e., through the association with cyclin T1) and
such a process is modulated by HEXIM1 [109].
Tamoxifen (Nolvadex), a selective ER modulator, has
been used for more than 30 years to treat patients with
advanced stage breast cancers [110]. However, tamoxifen
resistance is a major problem in the treatment of ER-positive
breast cancer patients. A recent study demonstrated that
treatment with tamoxifen induced HEXIM1 recruitment to
the promoters of ER target genes [111]. Since HEXIM1 was
known to compete with cyclin T1 for binding to ER𝛼, as
expected, decreases in the abundance of cyclin T1 and serine
2-phosphorylated RNAPII on the coding regions of ER
target genes were detected after tamoxifen treatment [111].
Furthermore, downregulation of HEXIM1 led to attenuation
of the inhibition caused by tamoxifen on estrogen-induced
gene expression and cell proliferation. Immunohistochemical
studies using the samples of breast cancer patients showed
that lower expression of HEXIM1 was associated with tumor
recurrence in tamoxifen-receiving patients, suggesting that
HEXIM1 is a critical determinant of tamoxifen resistance
[111].
HEXIM1 is also involved in tumor progression. Angio-
genesis is a physiological process governing the formation of
new blood vessels from pre-existing vessels and an essential
step in the transition of tumors from a benign state to a
malignant one. Vascular endothelial growth factor (VEGF)
functions as a major contributor to angiogenesis and its
expression can be induced by estrogens (via ER𝛼) or by
hypoxia (via hypoxia inducible factor-1 alpha (HIF-1𝛼)) [112].
HEXIM1 was found to regulate estrogen-induced VEGF
transcription by inhibiting the recruitment of ER𝛼 to the
VEGF promoter. Interestingly, HEXIM1 regulated this pro-
cess in a P-TEFb-independent fashion [113]. Under hypoxic
conditions, overexpression of HEXIM1 inhibited estrogen-
induced expression of hypoxia-inducible factor-1 alpha (HIF-
1𝛼) protein and blocked the recruitment of HIF-1𝛼 to the
promoter region of the VEGF gene [113]. HEXIM1 was
later found to directly interact with HIF-1𝛼 and increase
ubiquitination of HIF-1𝛼, resulting in downregulation of
HIF-1𝛼 protein expression [114].
Metastasis is the spreading of cancer cells from one organ
or tissue to another. The development of metastases and
angiogenesis are intrinsically connected [115]. The involve-
ment of HEXIM1 in angiogenesis suggests a potential role of
HEXIM1 in metastasis. A lower expression level of HEXIM1
was detected in metastatic breast cancers when compared
with matched primary breast tumors [116]. Overexpression
of HEXIM1, either by transgene expression or HMBA treat-
ment, significantly inhibited metastasis and angiogenesis
[116]. In addition, knockdown of HEXIM1 stimulated the
invasion of MCF7 cells [116]. Taken together, these results
suggest the tumor suppressor function of HEXIM1.
3.2. Regulation of HEXIM1 by NPM and MDM2. Results
obtained from mass spectrometry in search for novel
HEXIM1 binding proteins have led to the discovery of a
functional interaction between HEXIM1 and the p53 path-
way. Nucleophosmin (NPM; encoded by the NPM1 gene), a
nucleolar protein and a key regulator of p53, was identified
as a HEXIM1 binding partner [117]. NPM enhances p53
activity directly by binding to and stabilizing p53 or indirectly
by stimulating the induction of p53 through binding to
other p53 regulators, such as HDM2 and ARF [118–121].
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p53 (a.a. 370–386)
HEXIM1 (a.a. 150–161)
Figure 3: Alignment of the HDM2 ubiquitination sites between p53 (amino acids 370–386) andHEXIM1 (amino acids 150–161).TheHDM2-
ubiquitinated lysine residues are indicated in black boxes.
Mutation of the NPM1 gene is the most frequent mutation in
acute myeloid leukemia (AML). About 35% of AML patients
carrying NPMc+, the cytoplasmic-mislocated mutant form
of NPM, indicate the pathological significance of this gene
[122]. A distinct gene expression profile in NPMc+ AML cells
was reported in an early study [123]; however, the connec-
tion between NPM mutation and transcriptional regulation
remained to be elucidated.
We found that overexpression of NPM resulted in
proteasome-dependent degradation of HEXIM1 and activa-
tion of P-TEFb [117]. This result demonstrated the func-
tional significance of the HEXIM1-NPM interaction. The
interaction between HEXIM1 and NPMc+ was also detected
by immunoprecipitation (IP) [117]. In addition, using a
green fluorescent protein (GFP) tagged NPMc+ fusion pro-
tein, immunofluorescence studies demonstrated that GFP-
NPMc+ sequestered a portion of HEXIM1 in the cytoplasm
[117]. Such mislocalization of HEXIM1 in the cytoplasm
would have a significant impact on the equilibrium between
active and inactive P-TEFb complexes in the nuclei by
increasing the amounts of active P-TEFb complexes. In
agreement with this observation, the cytoplasmic localization
ofHEXIM1was only detected in anAMLcell line carrying the
NPMc+ mutation (i.e., AML3 cell line) [117]. Furthermore,
comparing the AML cell line with wild-type NPM, lower
HEXIM1 protein level was detected in AML3 cells [124]. As
expected, an increase in P-TEFb-mediated transcription was
detected in this NPMc+ AML cell line [117]. Collectively,
these findings demonstrate a role for the NPMc+mutation in
transcriptional regulation and suggest the potential involve-
ment of HEXIM1/P-TEFb in the tumorigenesis of AML.
MDM2 (or HDM2, the human homolog) is best-known
as the negative regulator of p53. HDM2 ubiquitinates p53
and leads to proteasome-mediated degradation of p53 [125,
126]. Six lysine residues, Lys-370, -372, -373, -381, -382,
and -386, located within the C-terminal negative (NEG)
domain of p53 are the target residues ofHDM2ubiquitination
[127] (Figure 3). Recently, HEXIM1 was identified as a novel
substrate of HDM2. Unexpectedly, the ubiquitination of
HEXIM1 by HDM2 does not lead to proteasome-dependent
degradation but still affects HEXIM1’s function [128]. Com-
pared to wild-type HEXIM1, ubiquitinated HEXIM1 exhibits
a stronger inhibitory effect on P-TEFb activity, suggesting a
potential role for HDM2 on regulation of P-TEFb [128]. Six
lysine residues located in the middle region of HEXIM1 were
identified as the major sites of HDM2 ubiquitination [128].
Sequence alignment of the ubiquitination sites between p53
(amino acids 370–386) and HEXIM1 (amino acids 150-161)
exhibits similar distribution of the lysine residues (Figure 3),
raising the possibility that HEXIM1 may compete with p53 in
binding to HDM2 and regulate the stability of p53.
3.3. HEXIM1 as a Positive Regulator of p53. Associations
between HEXIM1 and two p53 regulators, NPM and HDM2,
suggest the possible involvement of HEXIM1 in the p53 path-
way. Indeed, the interaction between endogenous HEXIM1
and p53 proteins was detected by IP. The direct binding
between HEXIM1 and p53 was demonstrated by an in vitro
GSTpull-down assay using the purified recombinant proteins
[129]. Overexpression of HEXIM1 upregulated the expression
levels of p53 and p53 target genes by blocking p53 ubiquitina-
tion mediated by HDM2 [129]. This was further supported
by domain study, showing that HEXIM1 is bound to p53
through the NEG region of p53 (Figure 4). As stated earlier,
the NEG domain contains six lysine residues ubiquitinated
by HDM2 [127] (Figure 4).This helps to explain that through
the interaction with the NEG region, HEXIM1 prevents
p53 ubiquitination by HDM2 and enhances the stability of
p53. In addition, it was noted that p53 interacted with the
7SK snRNA-free HEXIM1, indicating that HEXIM1 might
positively regulate p53 in a P-TEFb-independent manner
[129].
Importantly, HEXIM1 is an essential factor that regulates
the induction of p53. UV radiation or treatments with the
anticancer agents, such as doxorubicin, etoposide, flavopiri-
dol, roscovitine, and nutlin-3, are known to induce and
activate p53. In all conditions examined, elevated protein
levels of p53 were found to associate with the increased
p53-HEXIM1 interaction [129]. In contrast, knockdown of
HEXIM1 completely blocked p53 induction and released the
cell cycle arrest caused by p53 [129]. These findings reveal
a novel role of HEXIM1 in the activation of p53 induced
by anticancer agents and may lead to potential development
of new anticancer strategies. As the requirement of p53 for
angiogenesis and metastasis is wellestablished, it is possible
that HEXIM1 inhibits tumor progression through activation
of p53.
4. Conclusion
Involvement of Brd4 and HEXIM1 in tumorigenesis through
the P-TEFb-dependent and -independent mechanisms opens
a new and exciting venue for cancer research. Development
of small molecules or other strategies to block the chromatin-
binding of Brd4 or to induce the expression of HEXIM1 may
provide novel therapeutic options against cancer.
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Figure 4:HEXIM1 stabilizes p53 by blocking theHDM2-mediated ubiquitination of p53.Humanp53 protein can be divided into five domains:
transactivation (TA), proline rich (PR), DNA binding (DB), oligomerization (OLI), and negative (NEG) domains.The HDM2 ubiquitination
sites are located with the NEG domain. HEXIM1 interacts with the NEG domain of p53 and prevents the binding between p53 and HDM2.
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